Recent Updates
Recently added Catalysts
CTMX Positive Sentiment

CytomX Therapeutics Announces New Employment Inducement Grants

Thursday, May 16, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CytomX Therapeutics, a leader in biologics, announced the grant of stock options to two new employees, totaling 130,000 shares at an exercise price of $1.96. This grant is under its Employment Inducement Incentive Plan, designed to attract new talent to the company. Such initiatives may indicate a strategic effort to bolster the workforce and drive future growth.
Price reaction · baseline $1.96 (2024-05-15 close) · hit after-hours · clean, no other CTMX news in the window
day 0 close · peak
+2%

Market Sentiment Analysis

POSITIVE FACTORS

  • CytomX Therapeutics is expanding its workforce by creating new positions.
  • The stock options offered indicate a potential growth in employee investment and motivation.
  • The exercise price aligned with the market closing price shows a structured incentive.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
6.8%
average across 7 past catalysts
Cash runway
~54 mo
Minimal dilution risk
Lead asset
CX-2009
Phase 2 · Neoplasms

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company’s common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.
The stock options were granted pursuant to the Company’s 2019 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors in August 2020 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About CytomX Therapeutics
Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.
SVP, Finance and Accounting
Investor and Media Contact:

Frequently Asked Questions

What recent stock options did CytomX Therapeutics grant?

CytomX Therapeutics granted options to buy 130,000 shares at $1.96 each.

Who received the stock options from CytomX?

Two new employees were granted the stock options on May 15, 2024.

What plan governs the stock option grants at CytomX?

The options were granted under the 2019 Employment Inducement Incentive Plan.

When was the stock option plan approved by CytomX's board?

The plan was approved in August 2020 by CytomX's board of directors.

What is the trademark associated with CytomX Therapeutics?

Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

ShareAdd on Google
Tags: CTMX Viatris Investor Conferences Healthcare CytomX Therapeutics employment grants stock options biologics
Last updated: May 16, 2024

Biotech snapshot

Cash runway
$330M liquidity · $6M/mo burn
~54 mo
Minimal dilution risk
Lead asset
CX-2009Phase 2
Neoplasms →

Catalyst track record

+53%
best trade around CTMX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for CTMX.

See every catalyst's timing & PoA →